Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays - PubMed (original) (raw)
Comparative Study
. 2002 Oct 3;21(44):6848-57.
doi: 10.1038/sj.onc.1205868.
Thomas Thykjaer, Karin Tarte, Matthias Ensslen, Pierre Raynaud, Guilhem Requirand, Florence Pellet, Véronique Pantesco, Thierry Rème, Michel Jourdan, Jean-François Rossi, Torben Ørntoft, Bernard Klein
Affiliations
- PMID: 12360412
- DOI: 10.1038/sj.onc.1205868
Comparative Study
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays
John De Vos et al. Oncogene. 2002.
Abstract
The DNA microarray technology enables the identification of the large number of genes involved in the complex deregulation of cell homeostasis taking place in cancer. Using Affymetrix microarrays, we have compared the gene expression profiles of highly purified malignant plasma cells from nine patients with multiple myeloma (MM) and eight myeloma cell lines to those of highly purified nonmalignant plasma cells (eight samples) obtained by in vitro differentiation of peripheral blood B cells. Two unsupervised clustering algorithms classified these 25 samples into two distinct clusters: a malignant plasma cell cluster and a normal plasma cell cluster. Two hundred and fifty genes were significantly up-regulated and 159 down-regulated in malignant plasma samples compared to normal plasma samples. For some of these genes, an overexpression or downregulation of the encoded protein was confirmed (cyclin D1, c-myc, BMI-1, cystatin c, SPARC, RB). Two genes overexpressed in myeloma cells (ABL and cystathionine beta synthase) code for enzymes that could be a therapeutic target with specific drugs. These data provide a new insight into the understanding of myeloma disease and prefigure that the development of DNA microarray could help to develop an 'à la carte' treatment in cancer disease.
Similar articles
- Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.
Park ES, Shaughnessy JD Jr, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD Jr, Potter M, Janz S, Mushinski JF. Park ES, et al. BMC Genomics. 2007 Aug 31;8:302. doi: 10.1186/1471-2164-8-302. BMC Genomics. 2007. PMID: 17764563 Free PMC article. - Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y, Sakai A, Okikawa Y, Oue N, Asaoku H, Sasaki A, Imanaka F, Tsujimoto T, Takimoto Y, Masuda R, Nakaju N, Otsuki T, Yasui W, Kimura A. Katayama Y, et al. Int J Oncol. 2004 Sep;25(3):579-95. Int J Oncol. 2004. PMID: 15289859 - The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.
Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N, Shaughnessy J Jr, Klein B. Tarte K, et al. Br J Haematol. 2004 May;125(3):373-82. doi: 10.1111/j.1365-2141.2004.04908.x. Br J Haematol. 2004. PMID: 15086420 Free PMC article. - Plasma cell differentiation and multiple myeloma.
Shapiro-Shelef M, Calame K. Shapiro-Shelef M, et al. Curr Opin Immunol. 2004 Apr;16(2):226-34. doi: 10.1016/j.coi.2004.02.001. Curr Opin Immunol. 2004. PMID: 15023417 Review. - [Gene expression profiling of multiple myeloma].
Minvielle S. Minvielle S. Bull Cancer. 2003 Feb;90(2):127-30. Bull Cancer. 2003. PMID: 12660131 Review. French.
Cited by
- Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis.
Leung N, Comenzo R, Gillmore J, Havasi A, Kastritis E, Guthrie S, Signorovitch J, Heath D, Lousada I; Amyloidosis Forum Working Group Participants. Leung N, et al. Kidney Int Rep. 2024 Apr 4;9(7):1986-1994. doi: 10.1016/j.ekir.2024.03.033. eCollection 2024 Jul. Kidney Int Rep. 2024. PMID: 39081759 Free PMC article. Review. - Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.
Cardona-Benavides IJ, Misiewicz-Krzeminska I, Rojas EA, De Ramón C, Sanz-Solas A, Isidro I, Quwaider D, López-Guerrero AM, Cuadrado M, Calasanz MJ, Rosiñol L, Martínez-López J, San Miguel JF, Mateos MV, Corchete LA, Gutiérrez NC. Cardona-Benavides IJ, et al. Haematologica. 2024 Mar 1;109(3):877-887. doi: 10.3324/haematol.2023.283445. Haematologica. 2024. PMID: 37646661 Free PMC article. - The Triple Crown: NO, CO, and H2S in cancer cell biology.
Oza PP, Kashfi K. Oza PP, et al. Pharmacol Ther. 2023 Sep;249:108502. doi: 10.1016/j.pharmthera.2023.108502. Epub 2023 Jul 28. Pharmacol Ther. 2023. PMID: 37517510 Free PMC article. Review. - The BAFF-APRIL System in Cancer.
Ullah MA, Mackay F. Ullah MA, et al. Cancers (Basel). 2023 Mar 16;15(6):1791. doi: 10.3390/cancers15061791. Cancers (Basel). 2023. PMID: 36980677 Free PMC article. Review. - From drug repositioning to target repositioning: prediction of therapeutic targets using genetically perturbed transcriptomic signatures.
Namba S, Iwata M, Yamanishi Y. Namba S, et al. Bioinformatics. 2022 Jun 24;38(Suppl 1):i68-i76. doi: 10.1093/bioinformatics/btac240. Bioinformatics. 2022. PMID: 35758779 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous